DiaCarta

DiaCarta's business model revolves around providing highly sensitive diagnostic solutions to healthcare providers. These solutions are based on the company's proprietary technologies, including Xenonucleic Acid (XNA) and isobDNA™. The XNA technology enhances the sensitivity of platforms like qPCR and NGS by clamping to wild-type DNA sequences, which allows for the selective amplification of mutant target sequences. This is particularly useful for detecting rare genetic alterations found in early-stage cancer or for monitoring molecular residual disease. The company generates revenue through the sale of its diagnostic products and by offering clinical testing services from its ISO certified and CAP/CLIA certified laboratories in California and Nanjing, China.

The company's product portfolio includes solutions for early cancer detection, diagnosis, and therapy selection. Key offerings include ColoScape™, a blood or stool test for detecting colorectal cancer mutations, and RadTox™, a blood test that monitors changes in circulating cell-free DNA (cfDNA) to assess a patient's response to radiation and chemotherapy. DiaCarta also offers tests for bladder cancer, pan-cancer, and various infectious diseases, including HPV and formerly COVID-19. The company collaborates with pharmaceutical companies to develop companion diagnostics and has engaged in strategic partnerships to expand the commercialization of its tests, such as a collaboration with OncoAssure Ltd. for a prostate cancer prognostic test. In 2022, DiaCarta announced a planned merger with a special purpose acquisition company (SPAC), HH&L Acquisition Co., to become a publicly listed company, although this transaction was later canceled.